# SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD. Registered office: JAIPUR HOSPITAL, LAL KOTHI, NEAR SMS STADIUM, TONK ROAD, JAIPUR - 302015 (Rajasthan)

CIN: L85110RJ1989PLC005206

July 31, 2020

To,
The Manager,
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
MUMBAI – 400001

Scrip Code: - 524548

Sub: - Audited Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and Year ended on 31st March, 2020

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Audited Financial Results of Company for the Quarter and Year ended as on 31st March, 2020

Kindly take it on record and acknowledge the same.

Masi India Rospitals &

Thanking You,

For SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED.

SHAILENDRA KUMAR SHARMA

(Managing Director)

or Sharma Fast Rescurch Ltd.

Contact: 0141-2742266 / 2742619 E-mail - sharmaeastindia@gmail.com Fax: 0141-2742472 Website: www.jaipurhospital.co.in

#### SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED NEAR SMS STADIUM, LAL KOTHI, TONK ROAD JAIPUR

CIN: L85110RJ1989PLC005206

Statement of Standalone Audited Financial Results for the Quarter/Year Ended 31st March, 2020

(Rs. in lakhs)

-	Particulars	Quarter Ended			Year Ended	
S. No.		31.03.2020 (Audited)	31.12.2019 (Unaudited)	31.03.2019 (Audited)	31.03.2020 (Audited)	31.03.2019 (Audited)
	Income from Operations	202.40	388,00	446.50	1,616.73	1,472.90
	Revenue from Operations	393,49	(ACC-2020)	40.39	3.31	110.74
	Other Income	(3.19)	388,00	486.89	1,620.04	1,583.64
- 1	Total Revenue	390,30	388.00	400.07	1,000,005	- April 1
	Expenses		40.44	38.17	195.14	209.55
	Cost of materials consumed	39.38	1 1000000000000000000000000000000000000	11.43	4.65	11.43
	Purchase of stock in trade	1.17	25555	(1.30)	(0.25)	(1.30
	Change in Inventories of stock in trade	(0.40)	100000000000000000000000000000000000000	89.39	305.91	276.80
	Employee benefits expense	83.63	The second secon	28.00	115.39	87.97
	Finance cost	38.61	2004-01	12.84	42.86	52.12
	Depreciation and amortisation expense	10.14	C. C	285.58	918.63	912.68
(g)	Other Expenses	198.68		464.11	1,582.33	1,549.25
	Total Expenses	371.21	387.20	22.78	37.71	34.39
	Profit/(Loss) before exceptional items & tax (1-2)	19.09	0.80	22.78	3/./1	34.39
	Exceptional Items	-		40.00	****	24.70
	Profit/(Loss) before tax (3-4)	19.09	0.80	22.78	37.71	34.39
6	Tax expense					
	Current tax	5.88		5.38	5.88	6.62
	Taxation for Earlier year	(0.03)		(0.10)	(0.03)	(0.10
	Deferred tax	1.26		0.68	1.26	1.28
	TO SELECTION PROPERTY I	7.11	4	5.96	7.11	7.80
7	Profit/(Loss) for the period (5-6)	11.98	0.80	16.82	30.60	26.59
8	Other Comprehensive Income	950088	300000	2.022.2	15500-5	3000
00	Items that will not be reclassified to profit or loss	139	- 20	2	9.19	1.18
(0)	Income tax relating to items that will not be reclassified to				2000	13757
3	profit or loss				(0.96)	(0.12
	Other Comprehensive Income for the period	-			8.23	1.06
	Total Comprehensive Income (7+8)	11.98	0.80	16.82	38.83	27.65
10	Paid up equity share capital (face value of Rs. 10/- each)	328.38	328.38	328.38	328.38	328.3
11	Earning per share			2552000	1700000000	RASI0560
	Basic	0.36	0.02	0.51		
	Diluted	0.36		0.51	1.18	0.84
No	7. 7. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	340		0.51	1.18	0.84

These results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 31st July 2020.
 Audit Report on the above financial results has been received from the Statutory Auditors of the Company.

2. The figure of previous period/year have been re-grouped/re-arranged and / or recast wherever found necessary.

3. The amounts for three months ended 31st March 2020 are balancing amounts between the amounts as per addited accounts for the year ended 31st March 2020 and nine months ended on 31st December 2019

Pot Stell Rescal Rescal Counts for the year ended 31st per second rescal re

4. The Operations of the Company have been interrupted by Outbreak of COVID 19 & consequent lockdown in the Country since March 2020

For and on behalf of the Board of Directors

Date: 31.07.2020

SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED

Por MANAGING DIRECTOR
DIN 60432070 Hospitals &
Medical Research Ltd.

### SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED NEAR SMS STADIUM, TONK ROAD JAIPUR CIN: L85110RJ1989PLC005206

STATEMENT OF ASSETS AND LIABILITIES AS AT 31 MARCH 2020

(Rs.	in !	lake.	la
1305.	an e	100	w

Particulars	As at 31st March 2020	As at 31st March 2019
	2020	
ASSETS Non-Current Assets		
	440.91	472.73
(a) Property, Plant and Equipment (b)Capital work-in-progress	174.30	35.30
(c) Financial Assets	189.23	180.03
(i) Investments (ii) Others	14.52	14.62
(d) Deferred Tax Assets (Net)	2.20	2.66
(e) Other Non-Current Assets	2.20 821.16	705.34
Total Non- Current Assets	621.10	7000
Current Assets	06000	***
(a) Inventories	61.59	61.86
(b) Financial Assets	474.89	345.12
(i) Trade Receivable	10.37	513.56
(ii) Cash and Cash Equivalents	2.19	1.12
(iii) Bank balances other than (ii) above	2.19	3.22
(iv) Others	8.73	8.73
(b) Other Current Assets	606.95	577.70
Total Current Assets	1,164.72	1,508.09
Total Assets	1,985,88	2,213.43
Total Assets	2,700,100	
EQUITY AND LIABILITIES	000	
EQUITY	440.00	415.75
(a) Equity Share capital	415.75	
(b) Other Equity Total Equity	412.13 827.88	373.29 789.04
Total Equity		
LIABILITIES		
Non-Current Liabilities		
(a) Financial Liabilities	159.90	55.76
(i) Borrowings	137.70	
(ii) Other Financial Liabilities	17.63	50.50
(b) Deferred Tax Liability	34.00	15.42
(c) Other Non Current Liabilities Total Non - current liabilities	211.53	128.18
Total Non-Carlett Installes		
Current Liabilities		
(a) Financial Liabilities	#100 CH	14/10000
(i) Borrowings	529.63	992.91
(ii) Trade Payables	157.22	103.88
(iii) Other Financial Liabilities	224.58	157.81
(b) Other Current Liabilities	29.16	34.99
(c) Provisions Total Current liabilities	5.88 946.47	1,296.21
The second second second	14825.003	
Total Liabilities  Por Sharms   3  Total Equity and Liabilities Mi	1,158.00 Lindia Hospitals	a 1,424.39
Total Equity and Liabilities	gical Reseales.88	2,213.43
All Maria Companies	NP	- Approvin

### SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED JAIPUR HOSPITAL, NEAR SMS STADIUM, LAL KOTHI, TONK ROAD JAIPUR, RAJASTHAN CIN: L85110RJ1989PLC005206

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH 2020

(Amount in ₹ )

PARTICULARS	For the year ended March 31, 2020	For the year ended March 31, 2019	
Cash Flow from Operating Activities		34,39	
rofit before tax	37.71	34.37	
djustments to reconcile profit before tax to net cash flows:	10.00	52.12	
epreciation and impairment of property, plant and equipment	42.86	(98.30	
ain)/Loss on disposal of property, plant and equipment	(0.09)	(0.17	
terest income	115.34	81,12	
nance costs	0.05	1.23	
cremental Interest	(0.74)	0.79	
overnents in provisions	-	(7.21	
ther adjustments to reconcile profit or loss	195.13	63.97	
perating Profit before working capital changes	-		
/orking Capital Changes:	(23.00)	(5.26	
ncrease/(Decrease) in non current flabilities	(129.77)	(20.18	
increase)/Decrease in trade and other receivables and prepayments	(123.77)		
	(0.57)	2.00	
increase)/Decrease in other assets & Habilities	(29.26)	(182.43	
Increase)/Decrease in other current assets	0.27	2.43	
Increase)/Decrease in inventories	66.76	6.63	
ncrease/(Decrease) in other current financial liabilities	(5.82)	(15.04	
ncrease/(Decrease) in other current liabilities	53.35	11.32	
ncrease/(Decrease)in trade and other payables	127.09	(136.56	
ash Generated from Operations	(5.85)	(6.52	
ncome tax paid let Cash from Operating Activities (A)	121.24	(143.08	
3. Cash Flow from Investing Activities		222,07	
roceeds from sale of property, plant and equipment		222.07	
Purchase of property, plant and equipment (including Capital Work in	(150.03)	(57.15	
Progress)	0.09	0,17	
nterest recevied	(149.94)	165.09	
Net Cash used in Investing Activities(B)	(149,94)	103.07	
The section Activities			
C. Cash Flow from Financing Activities		- 754460	
Proceeds from / (Repayment of) Short Term Borrowings	(463.28)	581.03	
Proceeds from / (Repayment of) Long Term Borrowings	104.13	(25.59)	
Interest Paid	(115.34)	(81.12)	
Net cash used in Financing Activities (C)	(474.49)	474.32	
Net increase/(Decrease) in cash and cash equivalents(A+B+C)	(503.19)	496.33	
Control Supremer Land Andrew Control of	513,56	17.23	
Cash and cash equivalents at the beginning of the year	10.37	513.56	
Cash and cash equivalents at the thid of the year	70,07		
Cash and cash against the Cash and Cash			
No Rospials			
ot Summa Restartin Lid.			
Mark 10 Mark			

Note: The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.



## Amit Goyal & Co.

A-8, Il Floor, Ganpati Enclave, Ajmer Road, JAIPUR - 302 006 Tel.No.: 2225036, 2225065

Fax: 0141-2223211

E-mail: amitgoyalnco@yahoo.com

Independent Auditor's Report on the Quarterly and Year to Date Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended

To, The Board of Directors Sharma East India Hospitals & Medical Research Limited

Report on the audit of the Financial Results

Opinion

We have audited the accompanying Statement of Audited Financial Results for the Quarter and Year Ended March 31, 2020 ("Statement") of Sharma East India Hospitals & Medical Research Limited (the "Company"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- is presented in accordance with the requirements of the Listing Regulations in this regard; and
- gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2020,



### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

## Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies, making judgments and that are reasonable prudent; and and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

 Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the overland of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors
  - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion, our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during audit. We also provide those charged with

governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### Other Matter

- 1. The Statement includes the results for the quarter ended March 31, 2020 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2020 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.
- 2. Due to COVID-19 related lockdown, we were unable to observe the management's year-end physical verification of inventory. We have performed alternate procedure to audit the evidences of inventory as per guidance of SA 501 "Audit Evidence — Special consideration for selected items", which includes inspection of supporting documentation relating to purchases, sale and consumption of medicines, drugs, implants and surgical consumables, and have obtained sufficient appropriate audit evidence to issue our unmodified opinion on these financial results.

For Amit Goval & Co.

Chartered Accountants

ICAI Firm registration availaber: 003778C

Rajeev Kumar

Partner

Membership No. 075730

UDIN: 20075730AAAABE7210 Place: Jaipur

JAIPUR

Date: July 31, 2020

45

SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD.
Registered office: JAIPUR HOSPITAL, LAL KOTHI, NEAR SMS STADIUM, TONK
ROAD, JAIPUR - 302015 (Rajasthan)
CIN: L85110RJ1989PLC005206

July 31, 2020

To,
The Manager
Corporate Relationship Department
BSE Ltd.
25th Floor P.J. Towers,
Dalal Street, Fort,
MUMBAI-400 001.

Ref: Scrip Code:-524548- Sharma East India Hospitals And Medical Research Ltd.

Sub: - Declaration pursuant to Regulation 33 (3) (d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016.

Dear Sir.

DECLARATION

We, Shailendra Kumar Sharma, Managing Director and Vimal Kumar Joshi, Chief Financial Officer of Sharma East India Hospitals and Medical Research Limited (CIN: L85110RJ1989PLC005206) having its Registered Office at Jaipur Hospital, Near SMS Stadium, Lal Kothi, Tonk Road, Jaipur-302015, Rajasthan hereby declare that, the Statutory Auditors of the Company, M/s Amit Goyal & Co., Chartered Accountants (FRN: 003778C) have issued their Audit Report with unmodified opinion on Audited Financial Results of the Company for the quarter and financial year ended on 31st March, 2020.

This Declaration is given in compliance to Regulation 33 (3) (d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25th, 2016 and Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016

Kindly take this declaration on your records.

Thanking You,

FOR SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED

For Sharma I and India Hospitale &

Shailendfa Kumar Sharma

(Managing Director) DIN: 00432070

Por Sharma Past India Heaptish &

For Sharma Fast India Hospitals & Medical Research Lid

Vimal Kumar Joshi (Chief Financial Officer)

Por Sharma East India Hospitals & Medical Research Ltd.

Contact: 0141-2742266 / 2742619 E-mail - sharmaeastindia@gmail.com Fax: 0141-2742472 Website: www.jaipurhospital.co.in

SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD. Registered office: JAIPUR HOSPITAL, LAL KOTHI, NEAR SMS STADIUM, TONK ROAD, JAIPUR - 302015 (Rajasthan)

CIN: L85110RJ1989PLC005206

July 31, 2020

To, The Manager, Corporate Relationship Department, BSE Ltd. 25th Floor P.J. Towers, Dalal Street, Fort, MUMBAI-400 001.

Ref: Scrip Code:-524548 – Sharma East India Hospitals And Medical Research Ltd. Sub: - Outcome of Board Meeting held on 31st July, 2020 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Regulations").

Dear Sir/Ma'am,

The Board of Directors of the Company in their meeting held on July 31, 2020 at the registered office of the Company situated at Jaipur Hospital, Near SMS Stadium, Lal Kothi, Tonk Road, Jaipur at 04:00 P.M. to 11:00 P.M. inter alia transacted the

following business:

- Approved Audited Financial Results of the company for the quarter and financial year ended on 31st March, 2020 along with the Statement of Assets and Liabilities as on 31st March, 2020 and Cash Flow Statement for the year ended on 31st March, 2020 in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 (Listing Regulations). (Signed copy of the Audited Financial Results is enclosed herewith).
- 2. Took on record the Auditor's Report (With unmodified opinion) on the Audited Financial Results of the Company for the quarter and financial year ended on 31st March, 2020. Copy of Auditor's Report along with Declaration in compliance with Regulation 33 (3)(d) of the Listing Regulations, read with SEBI Circular CIR/CFD/CMD/56/2016 dated May 27, 2016 are enclosed herewith.
- 3. The Board took note of various Disclosures received from the Directors of the Company.
- 4. The Board took note of various Compliances for the Quarter and financial year ended on 31st March, 2020 pertinent to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take it on record and acknowledge the same.

Thanking You,

Yours faithfully,

Por Sharma for Indiport

For SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED

Medical Mostarch Ltd.

man india Haspitale & Shailendra Kulmar Sharma

Contact: 0141-2742266 / 2742619 E-mail - sharmaeastindia@gmail.com Fax: 0141-2742472 Website: www.jaipurhospital.co.in